BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Boehringer Mannheim GmbH, Germany, submitted on 30 June 1995, an application for 
marketing  authorisation  to  the  European  Evaluation  Medicines  Agency  (EMEA)  for  the  medicinal 
product  Rapilysin  10  U  through  the  centralised  procedure  falling  within  the  scope  of  Part  A  of  the 
Annex to Council Regulation No. (EC) 2309/93. 
The Rapporteur and the Co-Rapporteurs appointed by the CPMP were: 
Rapporteur   
Prof. D. A. Hildebrandt 
Co-Rapporteur  Dr. Jensen  
Licensing Status:  
Rapilysin 10 U has been given Marketing Authorisations in the following countries outside the EU: 
New Zealand 
Norway  
Slovakia 
Switzerland 
USA 
2. 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The  Rapporteur’s  initial  Assessment  Report  was  circulated  to  all  CPMP  Members  on 
30 October 1995 
The  Co-Rapporteur’s  initial  Assessment  Report  was  circulated  to  all  CPMP  Members  on 
30 October 1995 
The CPMP in its meeting on 19-21 December 1995 agreed on a consolidated list of questions as 
prepared by the Rapporteur and the Co-Rapporteur 
The  company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on 
4 March 1996. 
The Rapporteur circulated the comments on the company’s responses to the assessment report 
to all CPMP Members on 11 April 1996 
The Biotechnology Working Party report was forwarded to the CPMP on 13 May 1996. 
The  CPMP  during  their  meeting  of  21-23  May  1996  issued  a  positive  opinion  for  granting  a 
marketing authorisation for Rapilysin 10 U. 
1/1 
  EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
